ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
Y

ASH 2021 on the Efficacy and Safety of Cilta-cel in Len-Refractory Patients With Progressive MM After 1-3 Prior Lines of Therapy: Updated Results From CARTITUDE-2

By ASH 2021 Conference Coverage on VuMedi FEATURING Yael C. Cohen
By ASH 2021 Conference Coverage on VuMedi FEATURING Yael C. Cohen
51 views
January 26, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter
Myeloma
05:27
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Sustained Improvement in HRQoL in Transplant-Ineligible Pat…

Feat. A. Perrot
10:50
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Efficacy and Safety of Cilta-Cel in R/R MM: …

Feat. A. Jakubowiak
13:38
ASH 2021 Conference Coverage on VuMedi

2022 Updates on CAR T-Cell Therapy for Myeloma

Feat. L. Anderson
05:57
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Impact of EPd on HRQoL for Patients With R/R …

Feat. K. Weisel
05:25
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on the Efficacy and Safety of Cilta-cel in Len-Refractory P…

Feat. Y. C. Cohen
08:31
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updated Results From the Phase I CRB-402 Study of the BCMA-…

Feat. N. S. Raje
16:29
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Review of MRD in MM: Why, When, Where, and How?

Feat. N. S. Raje
13:12
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Addressing Current Questions and Controversies in the Mana…

Feat. M. Gertz
07:41
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Cilta-Cel for Triple-Class Exposed MM: Adjusted C…

Feat. M. Mateos
04:34
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on the Safety, Tolerability, PK/PD, and Preliminary Efficac…

Feat. N. Shah
04:19
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Risk of Infections With BCMA-Directed Immunotherapy in Mul…

Feat. M. Mohan
07:00
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on Outcomes in HR-MM Treated With Daratumumab

Feat. F. van Rhee
13:23
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Treatment Options for AL Amyloidosis Patients…

Feat. E. Kastritis
09:07
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Genomic and Immune Signatures Predict Sustained MRD Negati…

Feat. E. Boyle
06:08
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Efficacy and Safety of Ruxolitinib and Steroi…

Feat. J. Berenson
11:03
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Lecture on Clinical Outcomes of R/R MM Patients Following T…

Feat. T. Mouhieddine